TORONTO, Sept. 19 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that Dr. Denis Burger, Ms. Susan Koppy and Dr. Mark Vincent were elected to the Board of Directors of Lorus at the Annual General Meeting on September 19, 2007. Dr. Burger has been unanimously elected as the Chairman of the Board by the Board of the Directors.
Other members returning to Lorus' Board are Herbert Abramson, Chairman and CEO of Trapeze Capital Corp.; J. Kevin Buchi, EVP and CFO of Cephalon Inc.; Georg Ludwig, Managing Director of ConPharm Anstalt; Alan A. Steigrod, Managing Director of Newport Healthcare Ventures; Dr. Jim A. Wright, CEO of NuQuest Bio Inc.; and Dr. Aiping Young, President and CEO of Lorus Therapeutics Inc.
Denis R. Burger
Dr. Denis R. Burger has co-founded Trinity Biotech plc, based in Dublin, Ireland in June 1992 and acted as Chairman from 1992 to 1995 and now serves on the Board of Directors of the Company. Dr. Burger was the past Chairman, Chief Executive Officer and a director of AVI Biopharma Inc, an Oregon based biotechnology company. Dr. Burger is also a partner in Sovereign Ventures, a healthcare consulting and funding firm based in Portland, Oregon. He was a co-founder and, from 1981 to 1990, Chairman of Epitope Inc. In addition, Dr. Burger has held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health Sciences University in Portland. Dr. Burger received his Master of Science and PhD in Microbiology and Immunology from the University of Arizona.
Susan Koppy is the senior vice president, business and corporate
development of Idenix Pharmaceuticals since January 2006. Prior to joining
Idenix, Ms. Koppy was with Applied Biosystems, Inc. as vice president of
strategy and b
|SOURCE Lorus Therapeutics Inc.|
Copyright©2007 PR Newswire.
All rights reserved